RARA and primary cutaneous T-cell non-Hodgkin lymphoma: More recent human studies have demonstrated a direct effect of ATRA and RXR rexinoids on IL-2 receptor expression by human cutaneous T-cell lymphomas through RAR and RXR receptors (45,46).